3 Drugs Stocks Nudging The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 34 points (0.2%) at 16,585 as of Friday, May 9, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,493 issues advancing vs. 1,448 declining with 155 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 1.5%, Celgene ( CELG), up 1.2%, Gilead ( GILD), up 1.1%, Merck ( MRK), up 0.9% and Novo Nordisk A/S ( NVO), up 0.7%. On the negative front, top decliners within the industry include Mylan ( MYL), down 2.6%, AstraZeneca ( AZN), down 2.1%, Shire ( SHPG), down 1.3%, Teva Pharmaceutical Industries ( TEVA), down 0.9% and AbbVie ( ABBV), down 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Incyte ( INCY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Incyte is up $1.81 (3.6%) to $52.19 on light volume. Thus far, 540,663 shares of Incyte exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $49.64-$52.19 after having opened the day at $50.19 as compared to the previous trading day's close of $50.38.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. Incyte has a market cap of $8.7 billion and is part of the health care sector. Shares are down 0.5% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts who rate Incyte a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Incyte Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Novartis ( NVS) is up $0.65 (0.7%) to $88.56 on heavy volume. Thus far, 1.9 million shares of Novartis exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $88.18-$88.67 after having opened the day at $88.49 as compared to the previous trading day's close of $87.91.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $216.1 billion and is part of the health care sector. Shares are up 9.4% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts who rate Novartis a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, reasonable valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Illumina ( ILMN) is up $2.71 (1.9%) to $142.63 on light volume. Thus far, 402,948 shares of Illumina exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $138.06-$142.63 after having opened the day at $139.44 as compared to the previous trading day's close of $139.92.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $18.2 billion and is part of the health care sector. Shares are up 26.5% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook's Investors Have a Big Day Ahead

Facebook's Investors Have a Big Day Ahead

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

The Global Stock Market Rout Spreads Across the World

The Global Stock Market Rout Spreads Across the World

Comcast Details $30 Billion Bid for Britain's Sky in Takeover Battle With Fox

Comcast Details $30 Billion Bid for Britain's Sky in Takeover Battle With Fox